BioScrip Inc. (NASDAQ:BIOS) was down 2.9% during trading on Friday . The company traded as low as $2.65 and last traded at $2.67, with a volume of 188,836 shares trading hands. The stock had previously closed at $2.75.

Separately, Zacks Investment Research raised BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Monday, July 11th.

The company’s market capitalization is $301.78 million. The company’s 50 day moving average price is $2.68 and its 200-day moving average price is $2.45.

BioScrip (NASDAQ:BIOS) last issued its quarterly earnings data on Monday, August 8th. The company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.05. The firm earned $232.50 million during the quarter, compared to analysts’ expectations of $229.58 million. The business’s revenue for the quarter was down 11.4% compared to the same quarter last year. On average, equities research analysts anticipate that BioScrip Inc. will post ($0.27) earnings per share for the current fiscal year.

In other news, Director Coliseum Capital Management, L purchased 4,200,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 22nd. The shares were bought at an average cost of $2.00 per share, for a total transaction of $8,400,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David W. Golding purchased 12,500 shares of the company’s stock in a transaction that occurred on Friday, June 17th. The shares were purchased at an average price of $2.48 per share, for a total transaction of $31,000.00. Following the completion of the transaction, the director now directly owns 42,500 shares of the company’s stock, valued at $105,400. The disclosure for this purchase can be found here.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.